Clinical Trial Update: Study of Motexafin Gadolinium (MGd) for Second Line Treatment of Non-Small-Cell Lung Cancer [Phase 2]

View source ↗

Summary

This clinical trial update reports the completion of a Phase 2 study evaluating motexafin gadolinium as second-line treatment for non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Motexafin Gadolinium (motexafin gadolinium)

Snippet

Sponsor: Pharmacyclics LLC. | Conditions: Adenocarcinoma, Non-Small-Cell Lung Carcinoma | Phase 2 | Status: COMPLETED